Taken together, these results suggested that treatment with GCGR mAb could effectively attenuate the diabetes‐induced upregulation of CPT1B, OPA1, and MFN1, and oxidative stress in CMECs (Figure 5). This evidence concerns the gene MFN1 and diabetes mellitus.